Mounjaro® Fertigpen (Tirzepatid) – Gewichtsreduktion

Mounjaro and Wegovy are two different injectable weight-loss drugs with different mechanisms of action.

Wegovy contains the active ingredient semaglutide, which mimics a hormone called GLP-1 to regulate appetite and slow gastric emptying.

Wegovy also improves insulin sensitivity, stabilizes blood sugar levels, and prevents sudden spikes and drops to avoid excessive hunger signals from the brain.

Mounjaro contains another active ingredient, tirzepatide, which also mimics GLP-1 and additionally mimics another hormone called GIP to further enhance the body’s insulin secretion.

The two treatments also differ in their available dosage forms. Mounjaro is currently only available as a once-weekly injection. Wegovy is available as a once-weekly injection and, following MHRA approval on June 11, 2026, as a once-daily oral tablet containing semaglutide.

Wegovy tablets are the once-daily oral form of semaglutide and can now be ordered from Pharmica after completing an online consultation. They may be an option for patients who prefer not to use an injectable treatment. Mounjaro is not currently available in tablet form.

Mounjaro is not the same as Foundayo, although both are manufactured by Eli Lilly. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist, which is administered by injection once weekly. Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist, which is taken once daily as an oral tablet.

In the SURMOUNT-1 clinical trial, patients receiving the highest dose of Mounjaro lost an average of 22.5% of their body weight over 72 weeks. In the ATTAIN-1 trial, patients receiving the highest dose of Foundayo lost an average of approximately 11% of their body weight over the same period, although the two treatments were not directly compared.

Mounjaro is not the same as Ozempic. Although both medications are prescribed for weight loss, they contain different active ingredients and have different mechanisms of action.

Mounjaro contains tirzepatide, an active ingredient that mimics the hormones gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). Ozempic, on the other hand, contains semaglutide, an active ingredient that mimics the GLP-1 hormone but not the GIP hormone.

Yes, you can switch from Mounjaro to Wegovy. It is recommended that you wait at least 2 weeks after your last Mounjaro injection before starting Wegovy. This “washout” period allows the active ingredient from Mounjaro to be completely eliminated from your body and reduces the likelihood of unwanted interactions between Mounjaro and Wegovy.

When you start Wegovy, you will be prescribed the initial dose of 0.25 mg, even if you have previously used higher strengths of Mounjaro. This step is necessary to reduce the risk of side effects and also allows your body to adjust to the Wegovy active ingredient, semaglutide.

Semaglutide is also available as a once-daily tablet in the form of the Wegovy pill and may be clinically suitable for patients who do not wish to continue injectable treatment after switching.

Are you considering switching from Mounjaro to Wegovy? Our customer service team is happy to assist you. Our clinical team will also review your treatment to ensure that Wegovy is safe and suitable for you.

Orlistat is a clinically proven oral weight-loss treatment that reduces total calorie intake by limiting the absorption of dietary fat.

Mounjaro, on the other hand, is a weight-loss injection that works differently: it stabilizes blood sugar levels to reduce appetite and slows down gastric emptying, so you feel full for longer.

Mounjaro and Zepbound are both drugs containing the active ingredient tirzepatide, which mimics hormones to create a stronger feeling of fullness and reduce appetite.

Zepbound is the US name for the same weight-loss drug, while tirzepatide is licensed in the United Kingdom under the name Mounjaro.

The drugs work in the same way and are both prescribed for weight loss and metabolic regulation.

Mounjaro can reduce the effectiveness of oral contraceptive pills, especially during the first four weeks of treatment and after each dose increase. This is because the active ingredient tirzepatide slows gastric emptying, which can affect the absorption of the pill and reduce its effectiveness in preventing unplanned pregnancy.

Therefore, if you are using oral contraceptives (e.g., the combined pill or the progestogen-only pill) and taking Mounjaro, it is important to use an additional barrier method of contraception (e.g., condoms) for the first 4 weeks after starting treatment and for 4 weeks after each dose increase. During treatment with Mounjaro, you should also consider switching to long-acting contraceptive methods (e.g., an IUD).

Furthermore, diarrhea and vomiting are common side effects of Mounjaro, which can reduce the effectiveness of oral contraceptives. If vomiting occurs within three hours of taking your contraceptive pill, or if you have severe diarrhea for more than 24 hours, you should follow the instructions for a missed pill as outlined in the package leaflet for your contraceptive. If diarrhea or vomiting persists, you should also consider using an alternative non-oral method of contraception (e.g., an IUD or condoms).

Mounjaro can lead to a loss of body fat, which can affect the menstrual cycle in some women. This is because menstrual cycles are influenced by the level of the hormone estrogen, which is produced, among other places, in the body’s fat tissue.

Women who notice changes in their menstrual cycle while using Mounjaro are advised to consult a doctor for further advice.

The use of Mounjaro (tirzepatide) during pregnancy is not recommended due to limited data on its safety and effects on the development of the child.

If you are pregnant or planning a pregnancy and have used Mounjaro, discuss the use of this medicine with your doctor immediately.

You can purchase Mounjaro in Germany with a prescription from a fully registered and trusted online pharmacy like Schlankmeds. Our licensed prescribers and pharmacists can offer clinically proven prescription weight-loss treatments, as well as personalized nutrition and exercise recommendations as part of our comprehensive weight management service.

To order Mounjaro from Schlankmeds, simply fill out our short medical questionnaire. This will be reviewed by our clinical team to ensure the treatment is safe and suitable for you. Once approved, your medication will be discreetly delivered to you along with your Pharmica welcome pack.

Mounjaro should be stored in the refrigerator at 2°C to 8°C before use. Keep the pen in its original packaging until ready to use. Do not freeze.

After the first use, the Mounjaro pen can be stored at room temperature (not above 30°C) for up to 30 days or refrigerated until the next dose. Always replace the pen cap when not in use to protect the pen from light, as light exposure can reduce the effectiveness of the medication.